{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:35:27Z","timestamp":1791934527658,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Atobatele\u2019s grant and Nottingham Trent University Quality Research fund."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Androgen independency is associated with poor prostate cancer (PCa) survival. Here we report that silencing of transglutaminase-2 (TG2) expression by CRISPR-Cas9 is associated with upregulation of androgen receptor (AR) transcription in PCa cell lines. Knockout of TG2 reversed the migratory potential and anchorage independency of PC3 and DU145 cells and revealed a reduced level of mucin-1 (MUC1) RNA transcript through unbiased multi-omics profiling, which was restored by selective add-back of the truncated TG2 isoform (TGM2_v2). Silencing of AR resulted into increased MUC1 in TG2KO PC3 cells showing that TG2 affects transcriptional regulation of MUC1 via repressing AR expression. Treatment of PC3 WT cell line with TG2 inhibitor ZDON led to a significant increase in AR expression and decrease in MUC1. ZDON also blocked the formation of MUC1-multimers labelled with TG amine-donor substrates in reducing conditions, revealing for the first time a role for TG2, which we show to be externalised via extracellular vesicles, in MUC1 stabilisation via calcium-dependent transamidation. A specific antibody towards TGM2_v2 revealed its restricted nuclear location compared to the canonical long form of TG2 (TGM2_v1), which is predominantly cytosolic, suggesting that this form contributes to the previously suggested TG2-mediated NF-\u03baB activation and AR transcriptional repression. As TGM2_v2 transcription was increased in biopsies of early-stage prostate adenocarcinoma (PRAD) patients compared to subjects presenting inflammatory prostatitis, and total TG2 protein expression significantly increased in PRAD versus normal tissue, the role of TG2 and its truncated form as a prostate malignancy marker is suggested. In conclusion, this investigation has provided the first unbiased discovery of a novel pathway mediated by TG2 via MUC1, which is shown to contribute to androgen insensitivity and malignancy of PCa cells and be upregulated in PCa biopsies, with potential relevance to cancer immune evasion.<\/jats:p>","DOI":"10.1038\/s41419-023-05818-9","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:39:38Z","timestamp":1683704378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines"],"prefix":"10.1038","volume":"14","author":[{"given":"Adeola Grace","family":"Atobatele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-1048","authenticated-orcid":false,"given":"Elisa","family":"Tonoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakumar","family":"Vadakekolathu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Savoca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukti","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rossanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izhar","family":"Burhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"McArdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Caccamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9153-8997","authenticated-orcid":false,"given":"Elisabetta A. M.","family":"Verderio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"5818_CR1","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362:k3519.","journal-title":"BMJ"},{"key":"5818_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"5818_CR3","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.juro.2009.07.093","volume":"182","author":"KL Greene","year":"2009","unstructured":"Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232\u201341.","journal-title":"J Urol"},{"key":"5818_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015;527:329\u201335.","journal-title":"Nature"},{"key":"5818_CR5","doi-asserted-by":"crossref","unstructured":"Wong SK, Mohamad NV, Giaze TR, Chin KY, Mohamed N, Ima-Nirwana S. Prostate cancer and bone metastases: the underlying mechanisms. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20102587"},{"key":"5818_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32:1105\u201340.","journal-title":"Genes Dev"},{"key":"5818_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Mens Health. 2019;37:288\u201395.","journal-title":"World J Mens Health"},{"key":"5818_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J Med. 2010;363:411\u201322.","journal-title":"N. Engl J Med"},{"key":"5818_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34\u201345.","journal-title":"Nat Rev Cancer"},{"key":"5818_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s13046-019-1342-5","volume":"38","author":"S Pak","year":"2019","unstructured":"Pak S, Park S, Kim Y, Park JH, Park CH, Lee KJ, et al. The small molecule WNT\/beta-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. J Exp Clin Cancer Res. 2019;38:342.","journal-title":"J Exp Clin Cancer Res"},{"key":"5818_CR11","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/pros.23874","volume":"79","author":"A Kaipainen","year":"2019","unstructured":"Kaipainen A, Zhang A, Gil da Costa RM, Lucas J, Marck B, Matsumoto AM, et al. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion. Prostate 2019;79:1530\u201342.","journal-title":"Prostate"},{"key":"5818_CR12","first-page":"200","volume":"19","author":"DM Albala","year":"2017","unstructured":"Albala DM. Imaging and treatment recommendations in patients with castrate-resistant prostate cancer. Rev Urol. 2017;19:200\u20132.","journal-title":"Rev Urol"},{"key":"5818_CR13","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","volume":"16","author":"D Lorente","year":"2015","unstructured":"Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16:e279\u201392.","journal-title":"Lancet Oncol"},{"key":"5818_CR14","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/cncr.30587","volume":"123","author":"AJ Armstrong","year":"2017","unstructured":"Armstrong AJ, Saad F, Phung, Dmuchowski C, Shore ND, Fizazi K, et al. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer 2017;123:2303\u201311.","journal-title":"Cancer"},{"key":"5818_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.urology.2016.12.033","volume":"104","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, et al. The role of therapeutic layering in optimizing treatment for patients with castration-resistant prostate cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology 2017;104:150\u20139.","journal-title":"Urology"},{"key":"5818_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1593\/neo.121878","volume":"15","author":"B Yakubov","year":"2013","unstructured":"Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D. Extracellular tissue transglutaminase activates noncanonical NF-kappaB signaling and promotes metastasis in ovarian cancer. Neoplasia 2013;15:609\u201319.","journal-title":"Neoplasia"},{"key":"5818_CR17","doi-asserted-by":"publisher","first-page":"e74437","DOI":"10.1371\/journal.pone.0074437","volume":"8","author":"J Assi","year":"2013","unstructured":"Assi J, Srivastava G, Matta A, Chang MC, Walfish PG, Ralhan R. Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence. PLoS ONE. 2013;8:e74437.","journal-title":"PLoS ONE"},{"key":"5818_CR18","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/sj.onc.1210035","volume":"26","author":"LS Mangala","year":"2007","unstructured":"Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007;26:2459\u201370.","journal-title":"Oncogene"},{"key":"5818_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3727\/096504018X15149761920868","volume":"26","author":"HT Lee","year":"2018","unstructured":"Lee HT, Huang CH, Chen WC, Tsai CS, Chao YL, Liu SH, et al. Transglutaminase 2 promotes migration and invasion of lung cancer cells. Oncol Res. 2018;26:1175\u201382.","journal-title":"Oncol Res"},{"key":"5818_CR20","first-page":"138","volume":"12","author":"Y Bagatur","year":"2018","unstructured":"Bagatur Y, Ilter Akulke AZ, Bihorac A, Erdem M, Telci D. Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma. Cell Adh Migr. 2018;12:138\u201351.","journal-title":"Cell Adh Migr"},{"key":"5818_CR21","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00345-014-1462-7","volume":"33","author":"S Erdem","year":"2015","unstructured":"Erdem S, Yegen G, Telci D, Yildiz I, Tefik T, Issever H, et al. The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma. World J Urol. 2015;33:1553\u201360.","journal-title":"World J Urol"},{"key":"5818_CR22","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-17-2319","volume":"78","author":"S Condello","year":"2018","unstructured":"Condello S, Sima L, Ivan C, Cardenas H, Schiltz G, Mishra RK, et al. Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche. Cancer Res. 2018;78:2990\u20133001.","journal-title":"Cancer Res"},{"key":"5818_CR23","doi-asserted-by":"publisher","first-page":"e49321","DOI":"10.1371\/journal.pone.0049321","volume":"7","author":"S Kumar","year":"2012","unstructured":"Kumar S, Mehta K. Tissue transglutaminase constitutively activates HIF-1alpha promoter and nuclear factor-kappaB via a non-canonical pathway. PLoS ONE. 2012;7:e49321.","journal-title":"PLoS ONE"},{"key":"5818_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-14-0685-T","volume":"13","author":"ML Fisher","year":"2015","unstructured":"Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C. Transglutaminase is required for epidermal squamous cell carcinoma stem cell survival. Mol Cancer Res. 2015;13:1083\u201394.","journal-title":"Mol Cancer Res"},{"key":"5818_CR25","doi-asserted-by":"publisher","first-page":"9192","DOI":"10.1158\/0008-5472.CAN-09-1257","volume":"69","author":"M Shao","year":"2009","unstructured":"Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 2009;69:9192\u2013201.","journal-title":"Cancer Res"},{"key":"5818_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00726-011-1127-4","volume":"44","author":"VM Phatak","year":"2013","unstructured":"Phatak VM, Croft SM, Rameshaiah Setty SG, Scarpellini A, Hughes DC, Rees R, et al. Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer. Amino Acids. 2013;44:33\u201344.","journal-title":"Amino Acids"},{"key":"5818_CR27","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.ejca.2014.02.014","volume":"50","author":"AL Han","year":"2014","unstructured":"Han AL, Kumar S, Fok JY, Tyagi AK, Mehta K. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor. Eur J Cancer. 2014;50:1685\u201396.","journal-title":"Eur J Cancer"},{"key":"5818_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/pros.21344","volume":"71","author":"H Rajabi","year":"2011","unstructured":"Rajabi H, Joshi MD, Jin C, Ahmad R, Kufe D. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate 2011;71:1299\u2013308.","journal-title":"Prostate"},{"key":"5818_CR29","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-07-0307","volume":"67","author":"M Satpathy","year":"2007","unstructured":"Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, et al. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 2007;67:7194\u2013202.","journal-title":"Cancer Res"},{"key":"5818_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00432-009-0681-6","volume":"136","author":"KS Park","year":"2010","unstructured":"Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, et al. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:493\u2013502.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5818_CR31","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.bcp.2010.06.029","volume":"80","author":"K Mehta","year":"2010","unstructured":"Mehta K, Kumar A, Kim HI. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharm. 2010;80:1921\u20139.","journal-title":"Biochem Pharm"},{"key":"5818_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/onc.2009.342","volume":"29","author":"GY Jang","year":"2010","unstructured":"Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM, et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010;29:356\u201367.","journal-title":"Oncogene"},{"key":"5818_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbamcr.2012.10.011","volume":"1833","author":"S Gundemir","year":"2013","unstructured":"Gundemir S, Colak G, Feola J, Blouin R, Johnson GV. Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Biochim Biophys Acta. 2013;1833:1\u201310.","journal-title":"Biochim Biophys Acta"},{"key":"5818_CR34","doi-asserted-by":"publisher","first-page":"102242.","DOI":"10.1016\/j.jbc.2022.102242","volume":"298","author":"S Condello","year":"2022","unstructured":"Condello S, Prasad M, Atwani R, Matei D. Tissue transglutaminase activates integrin-linked kinase and beta-catenin in ovarian cancer. J Biol Chem. 2022;298:102242.","journal-title":"J Biol Chem."},{"key":"5818_CR35","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1073\/pnas.1017667108","volume":"108","author":"MA Antonyak","year":"2011","unstructured":"Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA. 2011;108:4852\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5818_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0204-5","volume":"9","author":"A Shinde","year":"2020","unstructured":"Shinde A, Paez JS, Libring S, Hopkins K, Solorio L, Wendt MK. Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. Oncogenesis 2020;9:16.","journal-title":"Oncogenesis"},{"key":"5818_CR37","doi-asserted-by":"crossref","unstructured":"Schwager SC, Young KM, Hapach LA, Carlson CM, Mosier JA, McArdle TJ, et al. Weakly migratory metastatic breast cancer cells activate fibroblasts via microvesicle-Tg2 to facilitate dissemination and metastasis. Elife. 2022;11.","DOI":"10.7554\/eLife.74433"},{"key":"5818_CR38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1681\/ASN.2017050479","volume":"29","author":"G Furini","year":"2018","unstructured":"Furini G, Schroeder N, Huang L, Boocock D, Scarpellini A, Coveney C, et al. Proteomic profiling reveals the transglutaminase-2 externalization pathway in kidneys after unilateral ureteric obstruction. J Am Soc Nephrol. 2018;29:880\u2013905.","journal-title":"J Am Soc Nephrol"},{"key":"5818_CR39","doi-asserted-by":"publisher","first-page":"102313","DOI":"10.1016\/j.pneurobio.2022.102313","volume":"216","author":"E Tonoli","year":"2022","unstructured":"Tonoli E, Verduci I, Gabrielli M, Prada I, Forcaia G, Coveney C, et al. Extracellular transglutaminase-2, nude or associated with astrocytic extracellular vesicles, modulates neuronal calcium homeostasis. Prog Neurobiol. 2022;216:102313.","journal-title":"Prog Neurobiol"},{"key":"5818_CR40","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.bbamcr.2016.05.005","volume":"1863","author":"L Diaz-Hidalgo","year":"2016","unstructured":"Diaz-Hidalgo L, Altuntas S, Rossin F, D\u2019Eletto M, Marsella C, Farrace MG, et al. Transglutaminase type 2-dependent selective recruitment of proteins into exosomes under stressful cellular conditions. Biochim Biophys Acta. 2016;1863:2084\u201392.","journal-title":"Biochim Biophys Acta"},{"key":"5818_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14219-6","volume":"11","author":"Y Yasumizu","year":"2020","unstructured":"Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, et al. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020;11:338.","journal-title":"Nat Commun"},{"key":"5818_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","volume":"9","author":"DW Kufe","year":"2009","unstructured":"Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874\u201385.","journal-title":"Nat Rev Cancer"},{"key":"5818_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-476","volume":"10","author":"TL Romanuik","year":"2009","unstructured":"Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, Sadar MD. Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics. 2009;10:476.","journal-title":"BMC Genomics"},{"key":"5818_CR44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1172\/JCI20032","volume":"113","author":"GV Glinsky","year":"2004","unstructured":"Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004;113:913\u201323.","journal-title":"J Clin Invest"},{"key":"5818_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239\u201343.","journal-title":"Nature"},{"key":"5818_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11\u201322.","journal-title":"Cancer Cell"},{"key":"5818_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1073\/pnas.0304146101","volume":"101","author":"J Lapointe","year":"2004","unstructured":"Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 2004;101:811\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5818_CR48","doi-asserted-by":"publisher","first-page":"18609","DOI":"10.1073\/pnas.0604844103","volume":"103","author":"MA Antonyak","year":"2006","unstructured":"Antonyak MA, Jansen JM, Miller AM, Ly TK, Endo M, Cerione RA. Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci USA. 2006;103:18609\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5818_CR49","doi-asserted-by":"publisher","first-page":"9119","DOI":"10.1074\/jbc.M115.699108","volume":"291","author":"G Singh","year":"2016","unstructured":"Singh G, Zhang J, Ma Y, Cerione RA, Antonyak MA. The different conformational states of tissue transglutaminase have opposing affects on cell viability. J Biol Chem. 2016;291:9119\u201332.","journal-title":"J Biol Chem"},{"key":"5818_CR50","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.1158\/0008-5472.CAN-06-1457","volume":"66","author":"AP Mann","year":"2006","unstructured":"Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res. 2006;66:8788\u201395.","journal-title":"Cancer Res"},{"key":"5818_CR51","doi-asserted-by":"publisher","first-page":"53725","DOI":"10.1074\/jbc.M407627200","volume":"279","author":"J Lee","year":"2004","unstructured":"Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, et al. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem. 2004;279:53725\u201335.","journal-title":"J Biol Chem"},{"key":"5818_CR52","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1158\/0008-5472.CAN-09-0523","volume":"69","author":"R Ahmad","year":"2009","unstructured":"Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009;69:7013\u201321.","journal-title":"Cancer Res"},{"key":"5818_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.339","volume":"6","author":"R Shrestha","year":"2015","unstructured":"Shrestha R, Tatsukawa H, Shrestha R, Ishibashi N, Matsuura T, Kagechika H, et al. Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis. 2015;6:e2002.","journal-title":"Cell Death Dis"},{"key":"5818_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1440-1746.2011.07009.x","volume":"27","author":"S Kojima","year":"2012","unstructured":"Kojima S, Kuo TF, Tatsukawa H. Regulation of transglutaminase-mediated hepatic cell death in alcoholic steatohepatitis and non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2012;27:52\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"5818_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0005-2736(00)00334-5","volume":"1510","author":"EH Moase","year":"2001","unstructured":"Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, et al. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta. 2001;1510:43\u201355.","journal-title":"Biochim Biophys Acta"},{"key":"5818_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10719-012-9437-7","volume":"30","author":"K Lavrsen","year":"2013","unstructured":"Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, Mandel U, et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J. 2013;30:227\u201336.","journal-title":"Glycoconj J"},{"key":"5818_CR57","first-page":"4000","volume":"55","author":"P Pandey","year":"1995","unstructured":"Pandey P, Kharbanda S, Kufe D. Association of the DF3\/MUC1 breast cancer antigen with Grb2 and the Sos\/Ras exchange protein. Cancer Res. 1995;55:4000\u20133.","journal-title":"Cancer Res"},{"key":"5818_CR58","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/1535-7163.MCT-10-0912","volume":"10","author":"M Khanna","year":"2011","unstructured":"Khanna M, Chelladurai B, Gavini A, Li L, Shao M, Courtney D, et al. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Mol Cancer Ther. 2011;10:626\u201336.","journal-title":"Mol Cancer Ther"},{"key":"5818_CR59","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1038\/onc.2011.429","volume":"31","author":"L Cao","year":"2012","unstructured":"Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012;31:2521\u201334.","journal-title":"Oncogene"},{"key":"5818_CR60","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1074\/jbc.273.20.11991","volume":"273","author":"M Lesort","year":"1998","unstructured":"Lesort M, Attanavanich K, Zhang J, Johnson GV. Distinct nuclear localization and activity of tissue transglutaminase. J Biol Chem. 1998;273:11991\u20134.","journal-title":"J Biol Chem"},{"key":"5818_CR61","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mc.22986","volume":"58","author":"RL Eckert","year":"2019","unstructured":"Eckert RL. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target. Mol Carcinog. 2019;58:837\u201353.","journal-title":"Mol Carcinog"},{"key":"5818_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27743-1","volume":"13","author":"JDA Sharpen","year":"2022","unstructured":"Sharpen JDA, Dolan B, Nystrom EEL, Birchenough GMH, Arike L, Martinez-Abad B, et al. Transglutaminase 3 crosslinks the secreted gel-forming mucus component Mucin-2 and stabilizes the colonic mucus layer. Nat Commun. 2022;13:45.","journal-title":"Nat Commun"},{"key":"5818_CR63","doi-asserted-by":"crossref","unstructured":"Wang Z, Moresco P, Yan R, Li J, Gao Y, Biasci D, et al. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack. Proc Natl Acad Sci USA. 2022;119.","DOI":"10.1073\/pnas.2119463119"},{"key":"5818_CR64","first-page":"605","volume":"28","author":"D Adler","year":"2011","unstructured":"Adler D, Lindstrot A, Buettner R, Wernert N. Analysis of laser-microdissected prostate cancer tissues reveals potential tumor markers. Int J Mol Med. 2011;28:605\u201311.","journal-title":"Int J Mol Med"},{"key":"5818_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/aja.2013.79","volume":"15","author":"Z Cao","year":"2013","unstructured":"Cao Z, Wang Y, Liu ZY, Zhang ZS, Ren SC, Yu YW, et al. Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes. Asian J Androl. 2013;15:742\u20136.","journal-title":"Asian J Androl"},{"key":"5818_CR66","doi-asserted-by":"crossref","unstructured":"Lopez-Bujanda ZA, Obradovic A, Nirschl TR, Crowley L, Macedo R, Papachristodoulou A, et al. TGM4: an immunogenic prostate-restricted antigen. J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2020-001649"},{"key":"5818_CR67","first-page":"257","volume":"6","author":"G Davies","year":"2007","unstructured":"Davies G, Ablin RJ, Mason MD, Jiang WG. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J Exp Ther Oncol. 2007;6:257\u201364.","journal-title":"J Exp Ther Oncol"},{"key":"5818_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-269","volume":"11","author":"WG Jiang","year":"2013","unstructured":"Jiang WG, Ye L, Sanders AJ, Ruge F, Kynaston HG, Ablin RJ, et al. Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain. J Transl Med. 2013;11:269.","journal-title":"J Transl Med"},{"key":"5818_CR69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.eururo.2005.12.035","volume":"49","author":"RB Marques","year":"2006","unstructured":"Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, et al. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol. 2006;49:245\u201357.","journal-title":"Eur Urol"},{"key":"5818_CR70","doi-asserted-by":"crossref","unstructured":"Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12.","DOI":"10.1126\/scitranslmed.aaz0463"},{"key":"5818_CR71","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05818-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:20:19Z","timestamp":1702372819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05818-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["5818"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-05818-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2223106\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}